Enveric Biosciences shares are trading higher after the company announced it named EB-003 as its lead drug candidate from its next-generation EVM301 Series. The company plans to initiate preclinical development of EB-003 in early 2024.

Enveric Biosciences Inc Ordinary Shares +10.95%

Enveric Biosciences Inc Ordinary Shares

ENVB

1.01

+10.95%

Enveric Biosciences shares are trading higher after the company announced it named EB-003 as its lead drug candidate from its next-generation EVM301 Series. The company plans to initiate preclinical development of EB-003 in early 2024.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via